NCT02775942View on ClinicalTrials.gov

Safety and Immunogenicity of IPOVAC in Young Children

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

July 25, 2016

Study Completion Date

October 31, 2016

Conditions
Poliomyelitis
Interventions
BIOLOGICAL

IMOVAC-POLIO

IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval

BIOLOGICAL

IPOVAC 1.5:5:5

IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form

BIOLOGICAL

IPOVAC, 3:10:10

IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form

BIOLOGICAL

IPOVAC, 6:20:20

IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form

Trial Locations (2)

Unknown

Preventive Medicine center, Thanh Sơn

Phu Tho Preventive Medicine Center, Việt Trì

All Listed Sponsors
collaborator

Ministry of Science and Technology, Vietnam

OTHER_GOV

lead

National Institute of Hygiene and Epidemiology, Vietnam

OTHER

NCT02775942 - Safety and Immunogenicity of IPOVAC in Young Children | Biotech Hunter | Biotech Hunter